Allergy Therapeutics PLC Publication of adjuvant studies in journals
July 06 2017 - 2:00AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
06 July 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Two studies of adjuvants in malaria and influenza vaccines
published in peer-reviewed journals
Publications demonstrate the potential of Allergy Therapeutics'
novel adjuvant systems in infectious diseases, further broadening
the product pipeline
6 July 2017 Allergy Therapeutics (AIM:AGY), the fully integrated
specialty pharmaceutical group specialising in allergy vaccines,
today announces that two preclinical studies carried out through
its Bencard Adjuvant Systems division have been published in
peer-review journals.
The two papers report that the novel depot adjuvant behind
Allergy Therapeutics' successful allergy immunotherapy Pollinex(R)
platform, microcrystalline tyrosine (MCT), both alone and in an
adjuvant system, have broad applications and elicit high, sustained
antibody titres demonstrating enhanced protective efficacy compared
to conventional adjuvants including aluminium.
Commenting on the recent publications, Manuel Llobet, Chief
Executive Officer of Allergy Therapeutics, said: "These
publications underpin the strategy for our Bencard Adjuvant Systems
division, which focuses on extending the use of MCT(R) and VLP in
further developing vaccines against unmet needs, and new and
emerging infectious diseases that require an effective depot
adjuvant."
The two publications are:
Comparison of a novel microcrystalline tyrosine adjuvant with
aluminium hydroxide for enhancing vaccination against seasonal
influenza: Heath et al., BMC Infectious Diseases (2017) 17:232
The paper authored by principal scientist Dr Matthew D. Heath
& collaborators from Public Health England discusses the use of
MCT(R) in a seasonal influenza vaccine model. The use of MCT(R)
displayed higher binding affinity compared to the conventional
depot adjuvant, aluminium, demonstrating the suitability of MCT(R)
as a depot adjuvant in applications outside of allergy
immunotherapy. MCT(R) elicited an immune response (HAI titre)
indicative of protection in a pre-clinical model. The data provide
evidence of the suitability of using the MCT(R) platform in an
influenza model and address some of the issues associated with
weakly stimulating vaccine targets/antigens.
Virus-like particle (VLP) plus microcrystalline tyrosine (MCT)
adjuvants enhance vaccine efficacy improving T and B cell
immunogenicity and protection against plasmodium berghei/vivax:
Cabral-Miranda et al., Vaccines (2017) 5;10.
This publication authored with The Jenner Institute at the
University of Oxford has been published investigating the use of
adjuvants MCT and adjuvant system MCT+VLP (AdSys-VCT) in malaria.
In a pre-clinical model, malaria antigens conjugated to VLP and
formulated in MCT induced highest antibody responses, highest
T-cell responses, and offered the best protection against malaria
compared with antigens formulated with aluminium. Moreover, the
study demonstrated that MCT(R) alone is able to elicit high and
sustained IgG antibody responses that are specific and protective
against P.vivax (malaria).
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Group sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries. Its
broad pipeline of products in clinical development include vaccines
for grass, tree and house dust mite, and peanut allergy, malaria
and influenza vaccines in pre-clinical development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities more than 11,000m(2) of state-of-the-art MHRA-approved
manufacturing facilities and laboratories. The Group employs c.500
employees and is listed on the London Stock Exchange (AIM:AGY). For
more information, please see www.allergytherapeutics.com.
About Bencard Adjuvant Systems
Bencard Adjuvant Systems is a division of Allergy Therapeutics
UK; based in Worthing, UK. The division specialises in developing
and optimising adjuvants for infectious diseases, cancer
immunotherapy and allergen immunotherapy and are committed to
engaging in long-term partnerships with those who require their
patented platform of adjuvant technologies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSIFMIFWSEDW
(END) Dow Jones Newswires
July 06, 2017 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024